Kiniksa Pharmaceuticals International, plc Current Income Tax Expense (Benefit)
Kiniksa Pharmaceuticals International, plc (KNSA) reported Current Income Tax Expense (Benefit) of $16.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc current income tax expense (benefit) for fiscal 2025 was $16.86M.
- Kiniksa Pharmaceuticals International, plc current income tax expense (benefit) for fiscal 2024 was -$1.09M, a 135.75% decline from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc current income tax expense (benefit) for fiscal 2023 was $3.05M, a 76.80% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc current income tax expense (benefit) for fiscal 2022 was $13.16M, a 857.64% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $16.86M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$1.09M 10-K · filed 2026-02-24 |
| 2023-12-31 | $3.05M 10-K · filed 2026-02-24 |
| 2022-12-31 | $13.16M 10-K · filed 2025-02-25 |
| 2021-12-31 | $1.37M 10-K · filed 2024-02-28 |
| 2020-12-31 | $791.00K 10-K · filed 2023-03-02 |
| 2019-12-31 | $1.11M 10-K · filed 2022-02-24 |
| 2018-12-31 | $764.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $199.00K 10-K · filed 2019-03-12 |